bioRxiv Science⌕ Search

Biology subjects

Redondo-Garcia, S.

Publications and source records attributed to Redondo-Garcia, S..

2 recordsLinked to original sources

Microenvironment-specific modulation of macrophage function and tumour progression by ADAMTS1 through Syndecan-4 shedding

Recent studies have emphasized the role of ADAMTS proteases in inflammation and immunity, particularly in the context of tumour progression. Since inflammatory cells can either constrain or promote tumour growth, understanding how ADAMTS proteases influence immune cell behaviour is crucial. Using syngeneic tumour models-B16F1 melanoma and Lewis Lung Carcinoma (LLC)-in Adamts1 knockout (Ats1-KO) mice, we observed model-specific outcomes underscoring the complexity of ADAMTS1 function in cancer. Transcriptomic and functional analyses revealed broad alterations in the matrisome and immune-related pathways across both tumour types. Strikingly, while tumour progression was impaired in B16F1-derived tumours, the LLC model-characterized by a stronger myeloid component-showed no dependency on Adamts1. To investigate this apparent resistance, we experimentally depleted macrophages and uncovered a profound functional defect in this population in Ats1-KO mice. In vitro assays confirmed reduced macrophage phagocytic activity. Mechanistically, we identified the transmembrane heparan sulfate proteoglycan syndecan-4 (SDC4), a known ADAMTS1 substrate, as a key mediator of this activity. Together, these findings reveal a previously unrecognized ADAMTS1-SDC4 axis that links extracellular matrix remodelling to macrophage phagocytosis, ultimately shaping tumour cell clearance and tumour progression.

cancer biology↗

VCAN is essential for ERK5-driven tumorigenesis in soft tissue sarcoma

The ERK5 signaling pathway has recently emerged as a critical regulator of soft tissue sarcoma (STS) biology, contributing to tumor initiation, progression, and maintenance. In this study, we identify VCAN, a chondroitin sulfate proteoglycan, as a novel transcriptional target of ERK5 and a central mediator of ERK5-related oncogenesis. Through a combination of genetic (silencing, overexpression) and pharmacological approaches, applied in both a chemically induced murine sarcoma model and several human STS cell lines, we demonstrate that ERK5 positively regulates VCAN expression. Functionally, VCAN silencing (by shRNAs) recapitulates the phenotypes of ERK5 silencing, including impaired migration, adhesion, proliferation, and tumorigenesis. Conversely, VCAN overexpression rescues these effects, confirming its essential role in ERK5-mediated oncogenesis. Furthermore, transcriptomic profiling reveals that VCAN accounts for a substantial portion of ERK5-regulated gene expression program. Analyses of human STS patient samples reveal significantly elevated mRNA levels of both VCAN and ERK5 compared to normal tissues. Notably, a strong correlation between VCAN and ERK5 expression, both at mRNA and protein levels, emerged in biopsies from leiomyosarcomas and undifferentiated pleomorphic sarcomas. Together, these findings uncover VCAN as a key effector in ERK5-driven tumorigenesis and highlight the ERK5/VCAN signaling axis as a promising therapeutic target in soft tissue sarcomas.

cancer biology↗